Takeda’s TAK-875 Could Take On Other Oral Antidiabetics, Early Data Suggest
This article was originally published in PharmAsia News
Executive Summary
Takeda’s novel GPR40 agonist TAK-875 has proven in Phase II to have blood sugar lowering on par with widely prescribed sulfonylureas, without causing hypoglycemia, and now moves into Phase III.